肿瘤患者静脉血栓栓塞症风险评估工具的应用研究

《肿瘤患者静脉血栓栓塞症风险评估工具的应用研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153572中国图书分类号R47HebeiMedicalUniversity硕士学位论文专业学位肿瘤患者静脉血栓栓塞症风险评估工具的应用研究研究生：杜慧姣导师：刘风侠副主任护师专业：护理学二级学院：第四医院2018年3月目录中文摘要············································································································1英文摘要····································

2、········································································3英文缩写············································································································5研究论文肿瘤患者静脉血栓栓塞症风险评估工具的应用研究引言······································································

3、······································6第一部分Khorana工具、Caprini工具筛选肿瘤患者静脉血栓栓塞症高风险者的Meta分析前言············································································································9材料与方法··················································································

4、··············9结果··········································································································11附图··········································································································13附表···············································

5、···························································17讨论··········································································································18小结··········································································································19参考文

6、献··································································································19第二部分Caprini风险评估工具在肿瘤化疗患者中的应用前言··········································································································28材料与方法········································

7、······················································28结果··········································································································31附图··········································································································33附表······

8、············